CHEK2 and cancer: More specifically, Cybulski and colleagues [159] estimated the lifetime BC risk for truncating CHEK2 mutations in Polish patients to be 20% in women without a family cancer history and 28% and 34% in women with a second- and first-degree relatives with BC, respectively.